1795 Meishi Announces Board Approval for Capital Increase in South Korean Subsidiary Alvogen Korea Holdings Ltd.
AI Summary (NQ-processed)
Meishi has announced that its board of directors has approved a capital increase in its 100%-owned South Korean subsidiary, Alvogen Korea Holdings Ltd., amounting to approximately USD 13.25 million, funded through the conversion of existing receivables into equity investment to enhance operational capital efficiency.
AI Analysis
Frequently Asked Questions
Q: What does Meishi do?
A: Meishi is a Taiwan-based pharmaceutical company focused on healthcare products and Asian markets.
Q: Who approved this capital increase?
A: Approved by the board of directors and audit committee, ensuring governance compliance.
Q: What does Alvogen Korea Holdings Ltd. do?
A: It is Meishi’s wholly-owned subsidiary responsible for drug development and distribution in Korea.
Q: How does exchange rate affect this transaction?
A: The amount is calculated using Taiwan Bank’s exchange rate, exposing it to FX risk.
Q: Will there be further capital increases?
A: Future capital actions may be considered based on financial and strategic needs.